Home Featured Page 281

Featured

Latest

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

The Benefits of Mescaline: How An Ancient Cactus Became a Future...

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the...

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill...

How Psychedelics Are Helping Advance Modern Technology

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Closer to Pure...

1...280281282...296 Page 281 of 296

EDITOR PICKS

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF

Religious Use of Psychedelics in the United States

The Farmer and The Cowman Should Be Friends: Why the Pharmaceutical...

The Problem and Paradox of Bad Trips, Part 2

The Benefits of Mescaline: How An Ancient Cactus Became a Future...

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the...

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill...

How Psychedelics Are Helping Advance Modern Technology

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Closer to Pure...

EDITOR PICKS

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY